Loading…
DIA Europe 2019 has ended
View analytic
Wednesday, February 6 • 16:45 - 18:00
#S0604: Outcomes Measurement: The Key to Value-Based Healthcare

Sign up or log in to save this to your schedule and see who's attending!

Tweet Share
Component Type: Session

The concept of Value Based Health Care (VBHC) is becoming a leading principle in hospitals to guide quality of care. In order to establish VHBC quality of care is measured with patient relevant outcomes using ICHOM (International Consortium for Health Outcomes Measurement) criteria. During this session we will introduce VBHC and the ICHOM outcomes but also discuss an example of breast cancer care for which VBHC and ICHOM have been used. Subsequently, different stakeholders such as industry, HTA, regulators and patients discuss to which extent VBHC and ICHOM could be relevant for the development of new drugs, for instance in breast cancer, and their value assessment by regulators and HTA.

Chair

Wim Goettsch, PhD, MSc

Speaker

Panelist
Annemarie Haverhals, MSc

Panelist
Adam Heathfield, PhD

Panelist
Niklas Hedberg, MPharm

Panel Discussion
Hubert G. M. Leufkens, PharmD


Speakers
avatar for Wim Goettsch

Wim Goettsch

Special Advisor HTA, Dutch National Health Care Institute (ZIN)
Wim Goettsch, PhD is currently Special Advisor HTA at the Dutch National Health Care Institute He was the Director of the EUnetHTA JA3 (2016-2020) Directorate between June 2016 and March 2018. He also has a position as an affiliate associate professor at Utrecht University (NL). He... Read More →
avatar for Annemarie Haverhals

Annemarie Haverhals

Independent Consultant On VBHC
Annemarie Haverhals is an independent healthcare consultant stimulating the implementation of value based healthcare delivery as a way to improve value for patients. Previously she was responsible for the design and implementation of Santeon’s Value Based Healthcare Program (Santeon... Read More →
avatar for Adam Heathfield

Adam Heathfield

Senior Director, Patient and Health Impact, Pfizer
Adam has worked for Pfizer for over 10 years. His current role is Senior Director in Pfizer’s Patient and Health Impact division. Previously, Adam has worked in Pfizer’s international policy division and led Pfizer’s work on science policy in Europe for several years. Adam initially... Read More →
avatar for Niklas Hedberg

Niklas Hedberg

Chair EUnetHTA Executive Board, Chief Pharmacist, Dental and Pharmaceutical Benefits Agency, TLV
Niklas Hedberg, MSc, is Chief Pharmacist for the Dental and Pharmaceuticals Benefits Agency (TLV) in Sweden. He is also Chair of the EUnetHTA Executive Board, TLV’s lead partner in EUnetHTA, and has led EUnetHTA WP3 – Evaluation since 2016. Mr. Hedberg has broad experience in... Read More →
avatar for Hubert Leufkens

Hubert Leufkens

Professor, Pharmaceutical Policy and Regulatory Science, Utrecht University
Hubert (Bert) G. Leufkens is professor of Pharmaceutical Policy and Regulatory Science at Utrecht University. He is research and policy-wise active at several (inter)national platforms on innovation, drug safety, pharmaceutical policy and regulatory science (e.g. past-member EMA Pharmacovigilance... Read More →

Wednesday February 6, 2019 16:45 - 18:00
K1 Austria Center Vienna Bruno-Kreisky-Platz 1 1220 Vienna Austria
  06 Access to Medicines, Session
  • Featured Topics Value and Access
  • Tags Session